Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients

References

• Jones HA, Antonini N, Hart AA, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol. 2009;27:4939–4947.
   PubMed Web of Science ®Google Scholar
• Kroman N, Holtveg H, Wohlfahrt J, et al. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer. 2004;100:688–693.
   PubMed Web of Science ®Google Scholar
• Dubsky PC, Gnant MF, Taucher S, et al. Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin Breast Cancer. 2002;3:65–72.
   PubMedGoogle Scholar
• Gnerlich JL, Deshpande AD, Jeffe DB, et al. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208:341–347.
   PubMed Web of Science ®Google Scholar
• El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer. 2006;6:194.
   PubMed Web of Science ®Google Scholar
• de la Rochefordiere A, Asselain B, Campana F, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet. 1993;341:1039–1043.
   PubMed Web of Science ®Google Scholar
• Laurberg T, Lyngholm CD, Christiansen P, et al. Long-term age-dependent failure pattern after breast-conserving therapy vs. mastectomy among Danish lymph-node-negative breast cancer patients. Radiother Oncol. 2016;120:98–106.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–10874.
   PubMed Web of Science ®Google Scholar
• Kyndi M, Sorensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–1426.
   PubMed Web of Science ®Google Scholar
• Mulligan AM, Pinnaduwage D, Bull SB, et al. Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort. Clin Cancer Res. 2008;14:4168–4174.
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–750.
   PubMed Web of Science ®Google Scholar
• Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684–1691.
   PubMed Web of Science ®Google Scholar
• Tramm T, Kyndi M, Myhre S, et al. Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer. Acta Oncol. 2014;53:1337–1346.
   PubMed Web of Science ®Google Scholar
• van der Hage JA, Mieog JS, van de Velde CJ, et al. Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials. Breast Cancer Res. 2011;13:R68.
   Google Scholar
• Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011;29:3885–3891.
   PubMed Web of Science ®Google Scholar
• Millar EK, Graham PH, O'Toole SA, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 2009;27:4701–4708.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–5374.
   PubMed Web of Science ®Google Scholar
• Lowery AJ, Kell MR, Glynn RW, et al. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133:831–841.
   PubMed Web of Science ®Google Scholar
• Metzger-Filho O, Sun Z, Viale G, et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 2013;31:3083–3090.
   PubMed Web of Science ®Google Scholar
• Ewertz M, Kempel MM, During M, et al. Breast conserving treatment in Denmark, 1989-1998. A nationwide population-based study of the Danish Breast Cancer Co-operative Group. Acta Oncol. 2008;47:682–690.
   PubMed Web of Science ®Google Scholar
• Christiansen P, Al-Suliman N, Bjerre K, et al. Recurrence pattern and prognosis in low-risk breast cancer patients-data from the DBCG 89-A programme. Acta Oncol. 2008;47:691–703.
   PubMed Web of Science ®Google Scholar
• Overgaard M, Christensen JJ. Postoperative radiotherapy in DBCG during 30 years. Techniques, indications and clinical radiobiological experience. Acta Oncol. 2008;47:639–653.
   PubMed Web of Science ®Google Scholar
• Rakha EA, Ellis IO. Lobular breast carcinoma and its variants. Semin Diagn Pathol. 2010;27:49–61.
   PubMed Web of Science ®Google Scholar
• Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 1977;40:1365–1385.
   PubMed Web of Science ®Google Scholar
• Tramm T, Hennig G, Kyndi M, et al. Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection. Virchows Arch. 2013;463:775–786.
   PubMed Web of Science ®Google Scholar
• Kyndi M, Sørensen FB, Knudsen H, et al. Tissue microarrays compared with whole sections and biochemical analyzes. A subgroup analysis of DBCG 82 b&c. Acta Oncol. 2008;47:591–599.
   PubMed Web of Science ®Google Scholar
• Andersen J, Bentzen SM, Poulsen HS. Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation. Eur J Cancer Clin Oncol. 1988;24:377–384.
   PubMedGoogle Scholar
• Albert JM, Gonzalez-Angulo AM, Guray M, et al. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys. 2010;77:1296–1302.
   PubMed Web of Science ®Google Scholar
• Selz J, Stevens D, Jouanneau L, et al. Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2012;84:1123–1132.
   PubMed Web of Science ®Google Scholar
• Cancello G, Maisonneuve P, Rotmensz N, et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat. 2011;127:713–720.
   PubMed Web of Science ®Google Scholar
• Truong PT, Sadek BT, Lesperance MF, et al. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy? Int J Radiat Oncol Biol Phys. 2014;88:57–64.
   PubMed Web of Science ®Google Scholar
• Sanpaolo P, Barbieri V, Genovesi D. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. Eur J Surg Oncol. 2011;37:876–882.
   PubMed Web of Science ®Google Scholar
• Mersin H, Gulben K, Berberoglu U, et al. Prognostic factors affecting postmastectomy locoregional recurrence in patients with early breast cancer: are intrinsic subtypes effective?. World J Surg. 2011;35:2196–2202.
   PubMed Web of Science ®Google Scholar
• Demirci S, Broadwater G, Marks LB, et al. Breast conservation therapy: the influence of molecular subtype and margins. Int J Radiat Oncol Biol Phys. 2012;83:814–820.
   PubMed Web of Science ®Google Scholar
• Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7:e1000279.
   PubMed Web of Science ®Google Scholar
• Henson KE, Jagsi R, Cutter D, et al. Inferring the effects of cancer treatment: divergent results from early breast cancer trialists' collaborative group meta-analyzes of randomized trials and observational data from SEER registries. J Clin Oncol. 2016;34:803–809.
   PubMed Web of Science ®Google Scholar
• Lyngholm CD, Laurberg T, Alsner J, et al. Failure pattern and survival after breast conserving therapy. Long-term results of the Danish Breast Cancer Group (DBCG) 89 TM cohort. Acta Oncol. 2016;55:983–992.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010;16:5222–5232.
   PubMed Web of Science ®Google Scholar
• Polley MY, Leung SC, McShane LM, et al. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013;105:1897–1906.
   PubMedGoogle Scholar
• Denkert C, Loib S, Müller BM, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol. 2013;24:2786–2793.
   PubMed Web of Science ®Google Scholar
• Bustreo S, Osella-Abate S, Cassoni P, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016;157:363–371.
   PubMed Web of Science ®Google Scholar
• Mannino M, Yarnold JR. Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: can radiotherapy ever be safely withheld? Radiother Oncol. 2009;90:14–22.
   PubMed Web of Science ®Google Scholar
• Bartelink H, Bourgier C, Elkhuizen P. Has partial breast irradiation by IORT or brachytherapy been prematurely introduced into the clinic?. Radiother Oncol. 2012;104:139–142.
   PubMed Web of Science ®Google Scholar
• Cao JQ, Olson RA, Tyldesley SK. Comparison of recurrence and survival rates after breast-conserving therapy and mastectomy in young women with breast cancer. Curr Oncol. 2013;20:e593–601.
   Web of Science ®Google Scholar
• Bantema-Joppe EJ, de ML, Visser O, et al. Early-stage young breast cancer patients: impact of local treatment on survival. Int J Radiat Oncol Biol Phys. 2011;81:e553–e559.
   Google Scholar
• van der Sangen MJ, van de Wiel FM, Poortmans PM, et al. Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged ≤40 years. Breast Cancer Res Treat. 2011;127:207–215.
   PubMed Web of Science ®Google Scholar
• Cao JQ, Truong PT, Olivotto IA, et al. Should women younger than 40 years of age with invasive breast cancer have a mastectomy? 15-year outcomes in a population-based cohort. Int J Radiat Oncol Biol Phys. 2014;90:509–517.
   PubMed Web of Science ®Google Scholar
• Mahmood U, Morris C, Neuner G, et al. Similar survival with breast conservation therapy or mastectomy in the management of young women with early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2012;83:1387–1393.
   PubMed Web of Science ®Google Scholar
• Jeon YW, Choi JE, Park HK, et al. Impact of local surgical treatment on survival in young women with T1 breast cancer: long-term results of a population-based cohort. Breast Cancer Res Treat. 2013;138:475–484.
   PubMed Web of Science ®Google Scholar